Skip to content
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
  • Investors & Media
  • Contact Us
  • Investors & Media
  • Contact Us
Ironwood Pharmaceuticals Logo
Ironwood Pharmaceuticals
Close
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions

Category: Uncategorized

Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Highlight-Clinical-Data-for-IW-3718-in-Persistent-Gastroesophageal-Reflux-Disease-GERD-at-Digestive-Disease-Week-2018/default.aspx

Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Highlight-Clinical-Data-for-IW-3718-in-Persistent-Gastroesophageal-Reflux-Disease-GERD-at-Digestive-Disease-Week-2018/default.aspx

Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Sends-Letter-to-Shareholders-Highlighting-Director-Nominees/default.aspx

Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Sends-Letter-to-Shareholders-Highlighting-Director-Nominees/default.aspx

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Files-Investor-Presentation-Highlighting-Actions-Taken-Designed-to-Unlock-Shareholder-Value/default.aspx

Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Files-Investor-Presentation-Highlighting-Actions-Taken-Designed-to-Unlock-Shareholder-Value/default.aspx

Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-and-Allergan-Announce-Settlement-with-Aurobindo-Pharma-Resolving-LINZESS-linaclotide-Patent-Litigation/default.aspx

Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-and-Allergan-Announce-Settlement-with-Aurobindo-Pharma-Resolving-LINZESS-linaclotide-Patent-Litigation/default.aspx

Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Files-Definitive-Proxy-Materials-and-Mails-Letter-to-Shareholders/default.aspx

Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders

https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Files-Definitive-Proxy-Materials-and-Mails-Letter-to-Shareholders/default.aspx

← Previous
Next →
Ironwood Pharmaceuticals Home
  • Investors & Media
  • Contact Us
Linkedin Twitter
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
  • Copyright © 2024 Ironwood. All rights reserved
  • Privacy Policy
  • Terms of Use
  • Company
    • Company Overview
    • Leadership
    • Open Payments & Transparency
  • Science & Medicine
    • Therapeutic Focus
    • Pipeline
    • Product
  • Patients
    • Overview
  • Responsibility
    • Overview
    • Diversity, Equity & Inclusion
    • Sustainability
    • Safety & Compliance
    • Patients & Research
    • Community Giving
  • Careers
    • Working at Ironwood
    • Internships, Co-ops
      and Fellowships
    • Open Positions
    • Investors & Media
    • Contact Us